SwRI receives grant to reduce the cost of current malaria treatment

Friday, June 29, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Institute explores novel two-step chemical approach

SAN ANTONIO, June 28, 2018 /PRNewswire/ -- Southwest Research Institute® (SwRI®) received a Bill

& Melinda Gates Foundation grant of $267,870 to develop new technology to lower the cost of artemisinin, the primary drug used to treat malaria.

Worldwide, malaria causes more than 400,000 deaths and 200 million visits for medical treatment annually, according to the World Health Organization. While artemisinin-based combination therapies (ACT) are greater than 90 percent effective at treating the disease, the cost of treatment exerts a heavy financial burden in the regions that experience the vast majority of malaria cases.

Malaria remains an important priority to the foundation, which has committed nearly $2 billion in grants to combat malaria. This grant focuses on novel approaches for manufacturing artemisinin treatment.

"Malaria is a huge problem affecting people worldwide," said Dr. Shawn Blumberg, a research scientist in SwRI's Chemistry and Chemical Engineering Division. "Malaria remains one of the oldest known diseases to plague humans. We will be working to develop a new chemistry technique to develop artemisinin treatment."

Currently, artemisinin is extracted from the sweet wormwood plant, which takes around eight-months to mature and yields about 15 grams of artemisinin for every kilogram of plant. Previous efforts to lower the cost of artemisinin involved the use of bioengineered yeast to produce artemisinic acid (AA), a synthetic precursor of the drug. This process, however, has yet to replace sweet wormwood as the primary source of the drug. SwRI will develop a novel process to utilize the more abundant Amorpha-4, 11-diene (AMD) as a cost-effective starting material to make high-quality, semisynthetic artemisinin.

"Based on our chemical expertise, we think this concept will deliver a viable, lower-cost artemisinin to inexpensively address one of humanity's most deadly infectious diseases," Blumberg said. "I'm excited to have this opportunity to address this issue."

SwRI is collaborating with Dr. Doug Frantz, who holds the Max and Minnie Tomerlin Voelcker Distinguished Professorship in Chemistry at The University of Texas at San Antonio, on this new technology. The grant was awarded in April 2018 and will run through April 2019.


For more information on SwRI drug product development, visit: https://www.swri.org/industries/drug-product-development.

About SwRI: SwRI is an independent, nonprofit, applied research and development organization based in San Antonio, Texas, with nearly 2,600 employees and an annual research volume of more than $528 million. Southwest Research Institute and SwRI are registered marks in the U.S. Patent and Trademark Office. For more information, please visit newsroom.swri.org or www.swri.org.

Contact: Tracey M.S. Whelan • (210) 522-2256 or twhelan@swri.org  

Cision View original content:http://www.prnewswire.com/news-releases/swri-receives-grant-to-reduce-the-cost-of-current-malaria-treatment-300674316.html

SOURCE Southwest Research Institute

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store